Sutro Biopharma

Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. FolRα-targeting ADC (STRO-002) Phase 1, anticipated preliminary data in ovarian cancer and EOP1/2 FDA meeting in 2H21. CD74-targeting ADC (STRO-001) Phase 1 dose-expansion to be initiated in 2H21. Pre-clinical data and IND projections for STRO-003 in general cancer anticipated for 2H21. BMS collaboration for CC-99712 (BCMA-targeting ADC) granted orphan drug designation in February 21. IND-enabling tox initiated for Merck collaboration on a cytokine derivative program.
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Infectious Disease, Oncology
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
310 Utah Ave
Suite 150
South San Francisco, CA 94080
United States

Company Participants at Sutro Biopharma STRO-002 Data Virtual KOL Event 2020

  • Annie Chang
  • Arturo Molina, MD, MS, FACP, Chief Medical Officer
  • Bill Newell, Chief Executive Officer
  • Edward Albini, Chief Financial Officer
  • Trevor Hallam, Ph.D., Chief Scientific Officer

Top 10 Holders of Sutro Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Franklin Advisers, Inc. 6.13 2,828,579 56.23 13F 6/30/21
Eventide Asset Management LLC 5.14 2,370,975 47.13 13F 6/30/21
State Street Corp. 4.84 2,233,692 44.41 13F 6/30/21
First Light Asset Management LLC 4.50 2,072,875 41.21 13F 6/30/21
Vanguard Group, Inc. (Subfiler) 4.34 2,001,775 39.80 13F 6/30/21
The Vanguard Group, Inc. 4.20 1,934,581 38.46 Funds 7/31/21
BlackRock Fund Advisors 4.14 1,908,674 37.94 13F 6/30/21
SV Health Investors LLC 3.96 1,824,542 36.27 13F 6/30/21
Baillie Gifford & Co. 3.89 1,794,173 35.67 13F 6/30/21
Suvretta Capital Management LLC 3.72 1,715,381 34.10 13F 6/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.